secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2024-04-17T23:59:59+00:00
Accession:  0001437749-24-012242
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree Therapeutics reports Q4 2023 net loss of $5.2M; cash only $4.3M as of Dec 31
--------------------------------------------------------------------------------

- Q4 net loss $5.2M ($0.95 per share) vs $9.7M ($13.01) in Q4 2022; FY net loss $20.3M ($5.24 per share).
- Cash and equivalents $4.3M at Dec 31, 2023; completed $1.5M convertible note bridge in April 2024 to fund operations through April.
- Acquired novel aPKCi inhibitor platform from Varian Biopharmaceuticals; includes topical and oral formulations.
- Licensed istaroxime and other CV assets to Lee's Pharmaceutical for Greater China; eligible for up to $138M milestones plus royalties.
- Two Phase 2 istaroxime trials in cardiogenic shock ongoing; data expected H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774924012242/0001437749-24-012242-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774924012242/wint20231117_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-012242

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer